US Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.20 BnPlaceholder estimate
Estimate 2025$1.38 Bn38.7% of the global market
Projected 2034$4.77 Bn 246.3%Adds $3.40 Bn over 9 forecast years
CAGR 2025–203414.8%Faster than 90% of 173 Medical Devices markets here
292 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Automated Insulin Delivery Systems Market Analysis Executive Summary
Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.
Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).
US Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Automated Insulin Delivery Systems Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Automated Insulin Delivery Systems Market in US
The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in US
Automated Insulin Delivery Systems in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 292 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in the US.[3] Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure for the US.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Component
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Medtronic
7.2 Tandem Diabetes Care
7.3 Insulet Corporation
7.4 Dexcom
7.5 Abbott Laboratories
7.6 Beta Bionics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The automated Insulin Delivery Systems market can be segmented based on various criteria, including component, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.
How big is the Automated Insulin Delivery Systems market in the US?
Placeholder estimate: about $1.38 Bn in 2025, rising to about $4.77 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in the US growing?
Placeholder estimate: about 14.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
Who regulates Automated Insulin Delivery Systems in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Automated Insulin Delivery Systems are running in the US?
292 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 17 Nov 2026.